# ECOG-ACRIN E1910

Source: https://onco.cc/trials/e1910/  
OnCo record `e1910` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Proved that adding the immunotherapy blinatumomab to standard treatment saves lives even in patients whose leukaemia was already undetectable.

## Summary

224 MRD-negative patients randomised. 3-year OS 85% vs 68% (HR 0.41, 95% CI 0.23-0.73); relapse-free survival 80% vs 64%. NEJM 2024. Basis for the June 2024 FDA approval of blinatumomab in consolidation regardless of MRD status; changed frontline adult ALL worldwide. Benefit persisted across age and MRD sensitivity.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT02003222
- Phase: 3
- Setting: Newly diagnosed Ph-negative B-ALL, age 30-70, in MRD-negative remission after induction: blinatumomab added to consolidation chemotherapy vs chemotherapy alone
- Sponsor: ECOG-ACRIN / NCI
- Enrolled: 488
- Result: 3-year OS 85% vs 68%; HR 0.41.
- Outcomes: Overall survival at 3 years (MRD-negative cohort): Blinatumomab + chemotherapy 85% vs Chemotherapy 68%, HR 0.41; Relapse-free survival at 3 years: Blinatumomab + chemotherapy 80% vs Chemotherapy 64%
- Replication: GMALL 08/2013 and the paediatric AALL1731 trial independently show blinatumomab improving outcomes when added to frontline therapy, in different age groups and risk strata.

## Sources

- ClinicalTrials.gov NCT02003222: https://clinicaltrials.gov/study/NCT02003222
- NEJM 2024: https://www.nejm.org/doi/full/10.1056/NEJMoa2312948

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Adolescent and young adult cancers (ages 15 to 39)](https://onco.cc/cancers/aya-cancers/), [High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)](https://onco.cc/cancers/all-paediatric-high-risk/), [Standard-risk B-cell acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-standard-risk/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD3](https://onco.cc/targets/cd3/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- companies: [ECOG-ACRIN Cancer Research Group](https://onco.cc/companies/ecog-acrin/)
- terms: [MRD-negative complete remission](https://onco.cc/terms/mrd-negative-cr/)
- people: [Mark R. Litzow](https://onco.cc/people/mark-litzow/)
- pairings: [Blinatumomab added to frontline chemotherapy](https://onco.cc/pairings/blinatumomab-frontline-consolidation/)
- key papers: [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/e1910.json